SCHEMBL1269799

SCHEMBL1269799

CCCC(=O)c1nc(NS(=O)(=O)c2ccc(Cl)cc2Cl)ccc1Sc1ccc(S(=O)(=O)N2CCCCC2)cc1

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PTGDR2 Q9Y5Y4 3/20 0.40
▸ PTGDR Q13258 1/20 0.40
▸ MAPT P10636 4/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ POLB P06746 1/20 0.40
▸ LMNA P02545 5/20 0.40
▸ HTT P42858 5/20 0.40
▸ MEN1 O00255 3/20 0.40
▸ KMT2A Q03164 3/20 0.40
▸ TP53 P04637 2/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ ALDH1A1 P00352 8/20 0.39
▸ MAPK1 P28482 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ KDM4E B2RXH2 2/20 0.38
▸ GAA P10253 2/20 0.37
▸ MCL1 Q07820 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1268503 0.99 PTGDR2 (0.41) PTGDR2PTGDRMAPTSMN1; SMN2POLB
SCHEMBL1269276 0.94 MAPT (0.41) PTGDR2PTGDRMAPTSMN1; SMN2POLB
SCHEMBL1268898 0.93 PTGDR2 (0.40) PTGDR2PTGDRMAPTSMN1; SMN2POLB
SCHEMBL1269706 0.92 ALDH1A1 (0.42) PTGDR2PTGDRMAPTSMN1; SMN2POLB
SCHEMBL1268583 0.91 ALDH1A1 (0.39) PTGDR2PTGDRMAPTSMN1; SMN2POLB
SCHEMBL1269823 0.90 CCKBR (0.41) MAPTSMN1; SMN2POLBLMNAHTT
SCHEMBL1269298 0.89 CCKBR (0.40) MAPTSMN1; SMN2POLBLMNAHTT
SCHEMBL1269786 0.89 PTGDR2 (0.46) PTGDR2PTGDRMAPTSMN1; SMN2POLB
SCHEMBL1268953 0.89 ALDH1A1 (0.45) PTGDR2PTGDRMAPTSMN1; SMN2POLB
SCHEMBL1268515 0.89 ALDH1A1 (0.41) PTGDR2PTGDRMAPTPOLBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7893077-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2011-02-22 — — US disclosed
US-7893077-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2011-02-22 — — US disclosed
US-7893077-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2011-02-22 — — US disclosed
EP-1786782-B1 BISARYL-SULFONAMIDES AMGEN INC (US) 2010-03-31 — — EP disclosed
US-20090221584-A1 Bisaryl-sulfonamides AMGEN INC. 2009-09-03 — — US disclosed
US-20090221584-A1 Bisaryl-sulfonamides AMGEN INC. 2009-09-03 — — US disclosed
US-20090221584-A1 Bisaryl-sulfonamides AMGEN INC. 2009-09-03 — — US disclosed
US-7544702-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2009-06-09 — — US disclosed
US-7544702-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2009-06-09 — — US disclosed
US-7544702-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2009-06-09 — — US disclosed
EP-1786782-A2 BISARYL-SULFONAMIDES Amgen Inc. (US) 2007-05-23 — — EP disclosed
US-20060084802-A1 Bisaryl-sulfonamides AMGEN INC. 2006-04-20 — — US disclosed
WO-2006020830-A2 BISARYL-SULFONAMIDES AMGEN INC. (US) 2006-02-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221584-A1 Bisaryl-sulfonamides PPARD, PPARA, PPARG PTGDR2 649/4885PTGDR 709/4885MAPT 4602/4885
US-20060084802-A1 Bisaryl-sulfonamides PPARD, PPARA, PPARG PTGDR2 649/4885PTGDR 709/4885MAPT 4602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback